title: Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials.
abstract: Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action resulting from reduced peripheral effects. This report provides an integrated summary of lipid changes at 26 weeks with BIL and comparator insulins (glargine, NPH) from phase III studies in type 1 diabetes (T1D), insulin-naïve patients with type 2 diabetes (T2D), patients with T2D on basal insulin only and patients with T2D on basal-bolus therapy. BIL treatment had little effect on HDL cholesterol and LDL cholesterol in all patients. The effect of both BIL and glargine treatment on triglycerides (TG) depended on whether patients had been previously treated with insulin. When BIL replaced conventional insulin glargine or NPH treatments, increases in TG levels were observed. When BIL or comparator insulins were given for 26 weeks to insulin-naïve patients with T2D, TG levels were unchanged from baseline with BIL but decreased with either glargine or NPH. The decreased peripheral action of BIL may reduce suppression of lipolysis in peripheral adipose tissue resulting in increased free fatty acid delivery to the liver and, hence, increased hepatic TG synthesis and secretion.
authors.affiliation: Irving Institute for Clinical and Translational Research, Columbia University, New York, New York, USA.
authors.forename: Henry
authors.initials: H
authors.lastname: Ginsberg
authors.affiliation: Department of Endocrinology, L'Institut du Thorax, CHU Nantes, Nantes, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Cariou
authors.affiliation: Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
authors.forename: Trevor
authors.initials: T
authors.lastname: Orchard
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana, USA.
authors.forename: Lei
authors.initials: L
authors.lastname: Chen
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana, USA.
authors.forename: Junxiang
authors.initials: J
authors.lastname: Luo
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana, USA.|Division of Endocrinology & Metabolism, Indiana University School of Medicine, Indianapolis, Indiana, USA.
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Bastyr
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana, USA.
authors.forename: Juliana
authors.initials: J
authors.lastname: Bue-Valleskey
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana, USA.
authors.forename: Annette M
authors.initials: AM
authors.lastname: Chang
authors.affiliation: Eli Lilly and Company, Budapest, Hungary.
authors.forename: Tibor
authors.initials: T
authors.lastname: Ivanyi
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana, USA.
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Jacober
authors.affiliation: Eli Lilly and Company, Indianapolis, Indiana, USA. hoogwerf_byron_james@lilly.com.
authors.forename: Byron J
authors.initials: BJ
authors.lastname: Hoogwerf
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000069036:Insulin Glargine / Q000008:administration & dosage / Q000494:pharmacology*; D061268:Insulin Lispro / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D007336:Insulin, Isophane / Q000008:administration & dosage / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects*; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000494:pharmacology*; D012189:Retrospective Studies; D014280:Triglycerides / Q000097:blood*
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069036:Insulin Glargine; D061268:Insulin Lispro; D007336:Insulin, Isophane; D008055:Lipids; D011092:Polyethylene Glycols; D014280:Triglycerides; C000621851:basal insulin peglispro
keywords: 
  NPH
  ; basal insulin peglispro; dyslipidaemia; insulin glargine; triglycerides